| Heat Biologics Inc (HTBX) | |||
|---|---|---|---|
| 2.38 0.01 (0.42%) | 05-03 00:00 | ||
| Open: | 2.41 | Pre. Close: | 2.37 |
| High: | 2.48 | Low: | 2.33 |
| Volume: | 43,610 | Market Cap: | 61(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 2.83 One year: 2.90 |
| Support: | Support1: 2.33 Support2: 1.94 |
| Resistance: | Resistance1: 2.42 Resistance2: 2.48 |
| Pivot: | 2.38 |
| Moving Averages: | MA(5): 2.38 MA(20): 2.38 MA(100): 2.38 MA(250): 2.67  |
| MACD: | MACD(12,26):  Signal(12,26,9): |
| %K %D: | %K(14,3): 33.33 %D(3): 33.33 |
| RSI: | RSI(14): 45.34 |
| 52-Week: | High: 10.85 Low: 1.6 Change(%): -46.8 |
| Average Vol(K): | 3-Month: 44 10-Days: 44 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 2.486 - 2.498 | 2.498 - 2.508 |
| Low: | 2.297 - 2.313 | 2.313 - 2.326 |
| Close: | 2.357 - 2.382 | 2.382 - 2.402 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HTBX ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 94 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: American Stock Exchange | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 25.40 |
| % Held by Insiders | 24290000.00 |
| % Held by Institutions | 5.20 |
| Shares Short (K) | |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -32930000.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | 587.3 |
| Return on Equity (ttm) | -17.1 |
| Qtrly Rev. Growth | 2110000.0 |
| Gross Profit (p.s.) | 5.333 |
| Sales Per Share | -103.733 |
| EBITDA (p.s.) | -55699996.000 |
| Qtrly Earnings Growth | -1.15 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -38.13 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.14 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
